BioMark Metabolic Panel

Etharums ser quidem rerum facilis dolores nemis omnis fugats vitaes nemo minima rerums unsers sadips amets.

BIOMARK METABOLIC PANEL ASSAYS

lung-cancer

BioMark has invested and successfully discovered and validated a new high-powered metabolic panel assay for early diagnosis of Lung Cancer. This performance panel assay has clinically demonstrated superior detection capabilities for early stage I / II Lung Cancers using urine and plasma. This is a major breakthrough in Lung Cancer diagnostics and strategically positions the company in a vintage position for high risk lung cancer screening market which currently uses low dose CT scans (LDCT). ML being incorporated in the analysis of the assay.

PANELS BEING DEVELOPED FOR OTHER CANCERS

  • Glioblastoma (GBM)
  • Breast Cancer
  • Head & Neck Cancer

Application:

  • Screening for high risk group
  • Precision medicine
  • Assess high risk relapse population cohort
  • Assess malignancy

Clinical Trials:

Spermidine/spermine N-acetyltransferase 1 (SSAT 1) Gene Expression in Human Cancer
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Status: Open

Spermidine/spermine N-acetyltransferase 1 (SSAT1) Gene Expression and Identification of High-Performance Metabolites in Human Cancer (Amended)
Principal Investigator: Dr. Andrew Maksymiuk, MD, Cancer Care Manitoba
Co-Investigator: Dr. Daniel S. Sitar, Ph.D, University of Manitoba
Co-Investigator: Dr. Paramjit Tappia, Ph.D, Asper Clinical Research Institute
Status: Open

Glioblastoma (GBM)

  • CancerCare Manitoba ethics approval obtained for the protocol
  • Patients to be recruited newly diagnosed and treated
  • Utilize both SSAT1 and new panels
  • Expand clinical trial sites in N. America

Breast Cancer

  • Identified and validated several putative markers
  • Expanding trial samples
  • Incorporate other clinical and imaging data

Head / Neck Cancer

  • In discussion with a major European centre to develop a comprehensive Omics panel of markers for high relapse cancer cohort
  • Modify protocol and potentially extend trial to additional North American sites after Health Canada and ethics approvals are granted.